A Dansyl Amide N-Oxide Fluorogenic Probe Based on a Bioorthogonal Decaging Reaction

Visible light sensing of ions by a cyanoquinoxaline 1,4-dioxide-based probe and its applications

Inducting newer fluorophores for colourimetry/fluorimetry-assisted analyte sensing is of great importance. Towards this end, we have shown the application of quinoxaline-1,4-dioxide bioactive molecules for the first time as potential probes for cations and anions. The molecule (ACQ) used in this study is soluble in water and provides specific colour output upon interaction with copper and palladium ions. Changing the solvent to DMSO allows a change in selectivity to fluoride ions via pink to blue colour change. All the ions detected showed quenching of the fluorescence signal upon interaction with the probe. Analysis of the Stern-Volmer plot indicated the predominant role of static quenching in the selective ion-sensing behaviour of the probe. The stoichiometry of the ACQ and ion was 2 : 1 in the case of Cu²⁺ and Pd²⁺, whereas a ratio of 1 : 1 was seen in the case of F^-. We have also applied ACQ to probe the above-mentioned analytes in practical settings.

Tailoring Materials for Epilepsy Imaging: From Biomarkers to Imaging Probes

Excising epileptic foci (EF) is the most efficient approach for treating drug-resistant epilepsy (DRE). However, owing to the vast heterogeneity of epilepsies, EF in one-third of patients cannot be accurately located, even after exhausting all current diagnostic strategies. Therefore, identifying biomarkers that truly represent the status of epilepsy and fabricating probes with high targeting specificity are prerequisites for identifying the "concealed" EF. However, no systematic summary of this topic has been published. Herein, the potential biomarkers of EF are first summarized and classified into three categories: functional, molecular, and structural aberrances during epileptogenesis, a procedure of nonepileptic brain biasing toward epileptic tissue. The materials used to fabricate these imaging probes and their performance in defining the EF in preclinical and clinical studies are highlighted. Finally, perspectives for developing the next generation of probes and their challenges in clinical translation are discussed. In general, this review can be helpful in guiding the development of imaging probes defining EF with improved accuracy and holds promise for increasing the number of DRE patients who are eligible for surgical intervention.